Panbela Therapeutics
Yahoo Finance • 12 months ago
Panbela Announces 2nd Independent Safety Review of the ASPIRE Registration Clinical Trial: Recommended Continuation with no Trial Modification
MINNEAPOLIS, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the indep... Full story
Yahoo Finance • last year
Panbela Provides Business Update and Reports Q3 2023 Financial Results
MINNEAPOLIS, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a busines... Full story
Yahoo Finance • last year
Panbela Therapeutics Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.9 Million Gross Proceeds Priced At-the-Market
MINNEAPOLIS, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, toda... Full story
Yahoo Finance • last year
Panbela Announces Publication of Preclinical and Clinical Data Titled: Inhibition of Polyamine Biosynthesis Preserves β Cell Function in Type 1 Diabetes
A Phase 1 clinical study showed that DFMO treatment may provide metabolic benefits to preserve β cell function and health in T1D. MINNEAPOLIS, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage... Full story
Yahoo Finance • last year
Acceptance of Polyamine Inhibitor CAR-T Combination Abstract for Online Publication
MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that an... Full story
Yahoo Finance • last year
Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023
MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it... Full story
Yahoo Finance • last year
Panbela Announces Issuance of New Patent in China for Claims of a Novel Process for the Production of SBP-101
MINNEAPOLIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced an Issue Notific... Full story
Yahoo Finance • last year
Panbela to Present at the LD Micro Investor Conference
MINNEAPOLIS, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, annou... Full story
Yahoo Finance • last year
Panbela Announces Issuance of New Patent in Chile for Claims of a Novel Process for the Production of Flynpovi
MINNEAPOLIS, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today... Full story
Yahoo Finance • last year
Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference
MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announ... Full story
Yahoo Finance • last year
Panbela Announces Issuance of New Patent in Europe for Claims of a Novel Process for the Production of SBP-101
MINNEAPOLIS, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today... Full story
Yahoo Finance • last year
Panbela Announces Issuance of New Patent in Australia Patent is for Claims of a Novel Process for the Production of SBP-101
MINNEAPOLIS, July 17, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today... Full story
Yahoo Finance • last year
Panbela Announces Preliminary Safety Analysis for ASPIRE Trial
MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the inde... Full story
Yahoo Finance • last year
Panbela Announces PACES S0820 Phase III Trial Passes Pre-Planned Futility Analysis
MINNEAPOLIS, June 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the SWO... Full story
Yahoo Finance • last year
Panbela Announces Poster Presentation at the Endocrine Society Meeting: Polyamine Inhibition and β-Cell Preservation in Recent Onset Type 1 Diabetes
MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announc... Full story
Yahoo Finance • last year
Panbela Announces Closing of Approximately $8.5 Million Public Offering
MINNEAPOLIS, June 21, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the clos... Full story
Yahoo Finance • last year
Panbela Announces Pricing of Approximately $8.5 Million Public Offering
MINNEAPOLIS, June 16, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the pri... Full story
Yahoo Finance • last year
Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy
MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced it has... Full story
Yahoo Finance • 2 years ago
Panbela Provides Business Update and Reports Q1 2023 Financial Results
MINNEAPOLIS, May 04, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business... Full story
Yahoo Finance • 2 years ago
Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023
MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it... Full story
